Exosome Immunomodulation Assays

Q: Can you test vesicles from both Gram-negative and Gram-positive bacteria?

Yes. Our protocols accommodate Gram-negative OMVs (from E. coli, Salmonella, Vibrio) and Gram-positive CMVs (from Lactobacillus, Bifidobacterium, Bacillus). We adjust dosing and controls based on the vesicle type, as Gram-negative OMVs carry LPS that contributes to immunostimulation while Gram-positive CMVs carry lipoteichoic acid with distinct immune engagement profiles.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

The therapeutic potential of microbial extracellular vesicles (mEVs) hinges on their ability to reprogram immune cell behavior—skewing macrophage polarization, suppressing pathogenic T-cell expansion, dampening pro-inflammatory cytokine storms, or stimulating regulatory pathways. Yet most vesicle characterization stops at particle counts and protein markers, leaving the critical question unanswered: does the preparation actually modulate the immune system in the intended direction?

At Creative BioMart Microbe, we address this gap with a comprehensive immunomodulation assay platform purpose-built for bacterial and probiotic vesicles. Our services span macrophage polarization profiling, T-cell proliferation inhibition, multi-cytokine quantification, dendritic cell maturation assessment, NK cell activity measurement, and NF-κB reporter assays. Each assay uses primary immune cells or established lines relevant to the therapeutic context, with vesicle doses normalized to both particle number and protein content. The platform integrates seamlessly with our broader Microbial Exosome Services portfolio, enabling clients to move from vesicle production through functional validation in a single coordinated workflow.

From anti-inflammatory probiotic EV candidates to OMV-based vaccine adjuvants, our immunomodulation data provide the dose-response evidence required for grant submissions, investor decks, and preclinical development programs. Contact us to discuss your mEV immunomodulation testing requirements.

Scientific workflow diagram showing six stages of exosome immunomodulation assay service: vesicle preparation, immune cell culture, co-incubation treatment, multi-parameter readout including cytokine panels and flow cytometry, data analysis, and comparative immunomodulation reporting, with each stage containing detailed laboratory illustrations.
Figure 1. Integrated workflow for microbial exosome immunomodulation assays, from vesicle preparation through multi-parameter immune cell readouts to functional classification.

Services

Service Details

Our immunomodulation assay portfolio covers the major immune cell types and signaling pathways relevant to microbial vesicle research. Each service is available as a standalone module or combined into a multi-cell-type profiling package. Vesicle preparations are tested across at least three dose levels to generate dose-response curves, and all assays include LPS-neutralized controls and vesicle-depleted supernatant references.

3D illustration of macrophage cells undergoing polarization from M1 to M2 phenotype after treatment with bacterial vesicles, shown with surface marker changes and color transition.

Macrophage Polarization Profiling

We evaluate mEV-driven macrophage polarization using flow cytometry for M1 (CD86, iNOS) and M2 (CD206, Arg-1) surface markers on RAW264.7 or primary bone marrow-derived macrophages. Cytokine secretion profiles and phagocytic activity are measured in parallel to classify immunomodulatory direction.

3D illustration of T-cell proliferation measured by CFSE dilution, showing progressive fluorescent signal reduction across cell divisions after vesicle treatment.

T-Cell Proliferation Inhibition Assays

We assess the capacity of mEVs to suppress or enhance T-cell proliferation using CFSE or EdU incorporation in anti-CD3/CD28-stimulated primary human or murine T cells. Proliferation indices are calculated from flow cytometry dilution profiles, with CD4⁺ and CD8⁺ subsets analyzed separately.

3D illustration of a multiplex cytokine bead array panel showing multiple fluorescent beads each capturing different cytokines, with a detection antibody adding signal.

Multi-Cytokine Panel Analysis

Our multiplex bead array and ELISA platform quantifies 20+ cytokines including TNF-α, IL-6, IL-1β, IL-10, IL-12, IFN-γ, IL-17, and TGF-β from immune cell culture supernatants. This panel captures both pro-inflammatory and regulatory responses in a single assay, enabling comprehensive immunomodulatory profiling.

3D illustration of a dendritic cell undergoing maturation after vesicle uptake, showing extended dendritic processes and surface expression of maturation markers.

Dendritic Cell Maturation Assays

We measure the impact of mEVs on dendritic cell maturation using CD80, CD86, CD40, and MHC-II surface expression by flow cytometry. Antigen-presenting capacity is evaluated through mixed lymphocyte reactions, and cytokine output is profiled to determine whether vesicles act as maturation stimuli or tolerogenic signals.

3D illustration of NK cells engaging target cells after vesicle treatment, showing activation marker upregulation and cytotoxic granule release at the immunological synapse.

NK Cell Activity Measurement

We evaluate natural killer cell activation and cytotoxic function after mEV treatment using CD69 and CD107a degranulation markers by flow cytometry, paired with calcein-release cytotoxicity assays against K562 target cells. This service is particularly relevant for oncolytic vesicle candidates and immune-activating OMV vaccine platforms.

3D illustration of a fluorescent reporter cell line with NF-kB promoter driving GFP expression, shown before and after vesicle treatment with visible signal induction.

NF-κB Reporter & Inflammasome Assays

We deploy stably transfected NF-κB-GFP reporter cell lines and NLRP3 inflammasome activation assays to dissect signaling pathway-level immunomodulation by mEVs. Reporter fluorescence quantification and caspase-1/IL-1β cleavage readouts provide mechanistic insight into how vesicles engage innate immune receptors.

Service Workflow

The immunomodulation assay workflow is organized into four macro-stages that accommodate both single-assay projects and multi-cell-type profiling packages.

Horizontal process flowchart showing four steps for exosome immunomodulation assays: vesicle preparation and dosing, immune cell co-culture, multi-parameter functional readout, and immunomodulation classification and reporting.

Inquiry

Assay Specifications & QC Standards

Immune Cell Panel & Readout Methods

Cell Type	Cell Model	Primary Readout
Macrophage	RAW264.7, THP-1, primary BMDM	M1/M2 markers (flow), cytokines, phagocytosis
T cell	Primary human/murine CD4⁺, CD8⁺	CFSE/EdU proliferation, activation markers
Dendritic cell	Primary moDC, MUTZ-3	Maturation markers, MLR, cytokine output
NK cell	Primary human NK, NK-92	CD69/CD107a, K562 cytotoxicity
Reporter line	NF-κB-GFP, NLRP3 reporter	Fluorescence quantification, caspase-1

Cytokine & Marker Readout Capabilities

Multiplex panel: 20+ cytokines in a single 25 µL sample (TNF-α, IL-6, IL-1β, IL-10, IL-12p70, IFN-γ, IL-17A, IL-23, TGF-β1, IL-4, IL-5, IL-13, GM-CSF, and more).
ELISA sensitivity: <1 pg/mL for key cytokines (TNF-α, IL-6, IL-10, IL-1β).
Flow cytometry: 8-color panels for surface and intracellular marker quantification.
Western blot: NF-κB pathway proteins (p65, IκBα, phospho-p65, phospho-IκBα) and inflammasome components.
RT-qPCR: Cytokine gene expression profiling for mechanistic studies.

Typical Data Range

Vesicle dose range: 10⁸–10¹¹ particles/mL per assay well (3+ dose levels).
Macrophage M2 shift: 15–60% increase in CD206⁺ population for immunomodulatory probiotic EVs.
T-cell proliferation inhibition: 20–70% reduction in proliferation index for regulatory mEVs.
Pro-inflammatory cytokine suppression: 30–70% reduction in TNF-α and IL-6 for anti-inflammatory EVs.
IL-10 induction: 2–10-fold increase for tolerogenic vesicle preparations.
Intra-assay CV ≤ 15%; inter-assay CV ≤ 20% for all quantitative endpoints.

Turnaround Time

Service Type	Timeline
Single cell-type assay (one vesicle preparation)	2–3 weeks
Multi-cell-type profiling (2+ cell types, one preparation)	3–5 weeks
Cytokine panel only (20+ cytokines, one preparation)	1–2 weeks
Comprehensive immunomodulation package (all cell types + cytokines)	5–8 weeks
Mechanism-of-action pathway analysis (NF-κB + inflammasome)	3–4 weeks
Expedited timeline	+50% fee, 40% time reduction

Timeline may vary based on cell type availability, number of vesicle doses, and assay complexity.

Quality Control

Vesicle dosing: Every batch normalized by NTA particle count and BCA protein concentration before immune cell exposure.
LPS control: Polymyxin B treatment and LAL assay on every vesicle preparation to quantify and control endotoxin contribution.
Vesicle-depleted supernatant: Parallel control to confirm that observed effects require intact vesicles.
Positive controls: LPS (inflammatory), dexamethasone (anti-inflammatory), and established probiotic EV references per assay.
Cell viability gate: All immune cell assays include viability staining; only viable cells are included in functional readouts.
Intra-assay CV ≤ 15%; inter-assay CV ≤ 20% for all quantitative endpoints.

Sample Requirements

Required Information	Optional Information	Not Accepted
Vesicle source organism (species and strain) Vesicle type (OMV, CMV, or mixed) Target immune cell type(s) of interest Expected immunomodulatory direction (pro- or anti-inflammatory) Vesicle particle concentration (NTA data preferred) Endotoxin level if known	Prior cytokine or proteomics data on vesicle cargo Specific signaling pathway of interest Reference compound or vesicle for benchmarking Preferred dose range or literature-based dosing Primary cell donor specifications (if applicable) Intended application (vaccine adjuvant, therapeutic, functional food)	Vesicle preparations with endotoxin >1 EU/mL without LPS neutralization plan Samples in buffers incompatible with cell culture Fixed or chemically modified vesicles Preparations with undefined microbial source Contaminated or mixed vesicle populations Samples shipped without cold-chain documentation

Recommended Sample Quantity by Assay Scope:

Assay Scope	Minimum	Recommended
Single cell-type assay	100 µL purified vesicles	200–300 µL
Multi-cell-type profiling (2+ types)	300 µL purified vesicles	500 µL–1 mL
Cytokine panel only	50 µL purified vesicles	100–200 µL
Comprehensive package (all cell types + cytokines)	500 µL purified vesicles	1–2 mL purified vesicles

Storage & Shipping: Ship purified vesicle suspensions on dry ice in sterile PBS. Include NTA data and endotoxin measurement if available. For primary cell assays requiring human donor cells, specify donor criteria and HLA restrictions if applicable. Avoid repeated freeze-thaw cycles; aliquot samples for multi-assay projects.

Inquiry

Our Advantages

Multi-Cell-Type Integration — Our platform profiles macrophages, T cells, dendritic cells, and NK cells from the same vesicle preparation, delivering a systems-level immunomodulatory assessment beyond single-assay services.
Endotoxin-Aware Design — We quantify endotoxin in every preparation and include polymyxin B controls, ensuring observed immune effects are attributed to vesicle cargo rather than contaminating PAMPs.
Dose-Response Standard — Every assay includes at least three vesicle dose levels to generate dose-response curves revealing thresholds, saturation, and biphasic effects for accurate potency characterization.
Mechanism-Level Readouts — We offer NF-κB reporter assays, NLRP3 inflammasome activation, and RT-qPCR pathway analysis to identify signaling mechanisms driving immune modulation.
Microbial Vesicle Specialization — Our protocols are optimized for bacterial OMVs and probiotic CMVs, accounting for their unique PAMP content and receptor engagement distinct from mammalian exosomes.

Applications

3D illustration of an inflamed tissue environment transitioning to a resolved state after treatment with probiotic vesicles, showing reduced inflammatory cell infiltration.

Anti-Inflammatory Therapeutic Development

Probiotic EV candidates screened for cytokine suppression and macrophage M2 polarization efficacy.

3D illustration of a vaccine vial with bacterial vesicles activating dendritic cells, shown with maturation marker upregulation and T-cell engagement.

OMV Vaccine Adjuvant Screening

Bacterial OMVs evaluated for dendritic cell maturation and T-cell activation capacity as vaccine platforms.

3D illustration of regulatory T cells expanding after vesicle treatment, shown with suppressive function markers dampening autoreactive effector T cells.

Autoimmune Disease Modulation

mEV candidates tested for T-cell proliferation inhibition and regulatory cytokine induction in autoimmune models.

3D illustration of an intestinal epithelial barrier with immune cells in the lamina propria responding to probiotic vesicle treatment, showing balanced cytokine production.

Gut Immune Homeostasis

Probiotic EVs profiled for intestinal macrophage modulation and mucosal immune balance in co-culture models.

Case Study

Case Study 1: Bifidobacterium longum EVs Induce Anti-Inflammatory Immune Modulation

Researchers isolated and characterized extracellular vesicles from Bifidobacterium longum AO44, a Gram-positive gut symbiont, and evaluated their immunomodulatory effects on mouse splenocytes and dendritic cell–T cell co-cultures. EV treatment induced a concentration-dependent increase in IL-10 secretion (anti-inflammatory cytokine) without affecting IL-17 levels. In co-culture systems, B. longum EVs enhanced IL-10 output from dendritic cell–CD4⁺ T cell interactions. Flow cytometry revealed increased frequencies of activated and proliferating CD4⁺ and CD8⁺ T cells (Ki67⁺, PD-1⁺), consistent with the IL-10 induction pattern. This study demonstrates that probiotic-derived EVs can actively reshape immune cell cytokine output and T-cell behavior, supporting their development as immunomodulatory therapeutics for inflammatory conditions.

Bar charts and flow cytometry dot plots showing IL-10 and IL-17 concentrations, CD4-positive and CD8-positive T-cell activation marker frequencies, and DC-CD4-positive T-cell co-culture cytokine profiles after treatment with Bifidobacterium longum extracellular vesicles at multiple concentrations.
Figure 2. Immune-modulatory activity of B. longum AO44 extracellular vesicles. (Mandelbaum, et al. 2023)

Case Study 2: Lactobacillus gasseri EVs Suppress Pro-Inflammatory Cytokines via TLR4/NF-κB Pathway

Investigators demonstrated that extracellular vesicles from Lactobacillus gasseri GFC-1220 (LEVs) significantly reduced pro-inflammatory cytokine production in LPS-stimulated RAW264.7 macrophages. LEV treatment suppressed NO production, PGE2 release, and the gene expression of iNOS and COX-2. At the cytokine level, LEVs inhibited IL-6, TNF-α, and IL-1β secretion in a dose-dependent manner, with corresponding reductions in gene expression. LEVs also reduced mitochondrial superoxide and ROS production by 71.7% and 56.7%, respectively. Co-treatment with the TLR4 inhibitor TAK-242 enhanced the anti-inflammatory effects of LEVs, supporting TLR4/NF-κB pathway involvement. Western blot confirmed reduced phosphorylation of IκBα and p65. This study illustrates how multi-parameter immunomodulation assays—spanning cytokine quantification, gene expression, pathway inhibitors, and Western blot—can comprehensively characterize the mechanism of probiotic EV immune modulation.

Bar charts showing dose-dependent suppression of NO and PGE2 secretion, iNOS and COX-2 gene expression, and IL-6, TNF-alpha, and IL-1beta secretion and gene expression in LPS-stimulated RAW264.7 macrophages treated with Lactobacillus gasseri extracellular vesicles.
Figure 3. Effects of LEVs on LPS-induced pro-inflammatory cytokines and mediators in RAW264.7 macrophages. (Koh, et al. 2025)

FAQs

Q: How do you control for endotoxin contributions in bacterial vesicle immunomodulation assays?

A: Every vesicle preparation is tested by LAL assay for endotoxin quantification. We include polymyxin B treatment controls to neutralize free LPS, and we compare intact vesicle effects with vesicle-depleted supernatant. For Gram-negative OMVs where LPS is an integral vesicle component, we report endotoxin levels alongside immunomodulation data and can perform LPS structural modification if needed.

Q: Which immune cell types can you test with microbial vesicles?

A: Our standard panel includes macrophages (RAW264.7, THP-1, primary BMDM), T cells (primary CD4⁺ and CD8⁺), dendritic cells (primary moDC, MUTZ-3), NK cells (primary, NK-92), and NF-κB/NLRP3 reporter cell lines. We can also accommodate intestinal epithelial co-culture models for gut-immune interaction studies.

Q: Do you use primary cells or cell lines?

A: We offer both. Established cell lines (RAW264.7, THP-1, NK-92) provide reproducible screening data at lower cost. Primary cells (human PBMC-derived T cells, monocyte-derived dendritic cells, murine BMDM) offer higher translational relevance for preclinical studies. For primary cell assays, we recommend multi-donor testing to account for donor variability.

Q: How many vesicle dose levels do you test?

A: Our standard protocol includes a minimum of three dose levels (typically 10⁸, 10⁹, and 10¹⁰ particles/mL) to generate dose-response curves. For comprehensive profiling or publication-quality data, we recommend five dose levels. The dose range can be adjusted based on prior literature or client specifications.

Q: Can you perform mechanism-of-action studies beyond phenotypic readouts?

A: Yes. Our NF-κB-GFP reporter assays, NLRP3 inflammasome activation readouts, TLR4 inhibitor (TAK-242) experiments, and RT-qPCR pathway analysis provide mechanistic insight into how vesicles engage innate immune receptors. Western blot for pathway proteins (phospho-p65, IκBα, cleaved caspase-1) is available for publication-grade mechanistic data.

Q: Can you test vesicles from both Gram-negative and Gram-positive bacteria?

A: Yes. Our protocols accommodate Gram-negative OMVs (from E. coli, Salmonella, Vibrio) and Gram-positive CMVs (from Lactobacillus, Bifidobacterium, Bacillus). We adjust dosing and controls based on the vesicle type, as Gram-negative OMVs carry LPS that contributes to immunostimulation while Gram-positive CMVs carry lipoteichoic acid with distinct immune engagement profiles.

Q: What controls are included in every immunomodulation assay?

A: Every assay includes: untreated cells (baseline), LPS-stimulated cells (positive inflammatory control), dexamethasone-treated cells (positive anti-inflammatory control), vesicle-depleted supernatant (confirms intact vesicle requirement), and heat-inactivated vesicles (confirms protein cargo dependence). For multi-dose studies, each dose level includes its own vehicle control.

Q: Can immunomodulation data support regulatory submissions?

A: Our reports include full raw data, control panels, statistical analysis, and method documentation suitable for preclinical regulatory packages. For clients advancing toward GMP-Grade production, we can establish immunomodulatory potency assays as release criteria with validated protocols and acceptance criteria.

References:

Mandelbaum, N., et al. (2023). Extracellular vesicles of the Gram-positive gut symbiont Bifidobacterium longum induce immune-modulatory, anti-inflammatory effects. npj Biofilms and Microbiomes, 9, 30.
Koh, J.-A., et al. (2025). Extracellular vesicles derived from Lactobacillus gasseri GFC-1220 alleviate inflammation via the TLR4/NF-κB signaling pathway in LPS-stimulated RAW264.7 macrophages. Scientific Reports, 15, 21381.

Services

Inquiry